In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amphastar Pharmaceuticals (AMPH – Research Report), with a price target of $71.00. The company’s shares closed yesterday at $55.74.
According to TipRanks, Amsellem is an analyst with an average return of -6.4% and a 37.80% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Alkermes, Revance Therapeutics, and Supernus Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amphastar Pharmaceuticals with a $63.00 average price target, a 13.02% upside from current levels. In a report released on November 24, DBS also maintained a Buy rating on the stock with a $55.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Amphastar Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $180.56 million and a net profit of $49.22 million. In comparison, last year the company earned a revenue of $120.13 million and had a net profit of $15.87 million
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amphastar Pharmaceuticals (AMPH) Company Description:
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
Read More on AMPH:
